← Eichor
Condition: Non Metastatic Castration Resistant Prostate Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Non Metastatic Castration Resistant Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Working Out M0 Bipolar Androgen Therapy
Phase 2 · 12 location(s) · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prost
Phase 1/Phase 2 · 2 location(s) · Yunhe Pharmaceutical (Tianjin) Co., Ltd · NCT06970119Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07290270A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With
Phase 1 · 11 location(s) · Atridia Pty Ltd. · NCT06830850A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · 83 location(s) · Pfizer · NCT03460977A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 24 location(s) · DualityBio Inc. · NCT05785741An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Phase N/A · 1 location(s) · Bayer · NCT06334120A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Phase 1 · 1 location(s) · TechnoGenesys, Inc. · NCT06705686A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Add
Phase 4 · 25 location(s) · Bayer · NCT05348876A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · SHY Therapeutics · NCT07705334A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Post Marketing Study on Pluvicto in Korea
Phase N/A · 12 location(s) · Novartis Pharmaceuticals · NCT06514521A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 · 15 location(s) · IDEAYA Biosciences · NCT07503808Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 · 8 location(s) · Orano Med Theranostics, SAS · NCT05283330Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Phase 2 · 44 location(s) · Pfizer · NCT04606446Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT05168618PROCARE - PROstate Cancer Real World Evidence Registry
Phase N/A · 53 location(s) · UroTrials Company (GmbH) · NCT06835218A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/Phase 2 · 81 location(s) · Novartis Pharmaceuticals · NCT04104776
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.